SCHEMBL29655554

SCHEMBL29655554

[2H]C([2H])([2H])NC(=O)c1cc2c(F)cc(F)cc2[nH]1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.46
EIF4A3 P38919 1/20 0.44
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
GHSR Q92847 1/20 0.37
IDO1 P14902 5/20 0.36
TDO2 P48775 5/20 0.36
KDM4E B2RXH2 2/20 0.36
PDPK1 O15530 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
HPGD P15428 1/20 0.36
TSHR P16473 1/20 0.36
NFKB1 P19838 1/20 0.36
APEX1 P27695 1/20 0.36
CYP2C19 P33261 1/20 0.36
HSD17B10 Q99714 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
ALOX15 P16050 1/20 0.35
FBP1 P09467 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18183345 0.89 CNR1 (0.48) CNR1EIF4A3MEN1KMT2AGHSR
SCHEMBL16234661 0.78 EIF4A3 (0.51) CNR1EIF4A3IDO1TDO2KDM4E
SCHEMBL1144892 0.77 EIF4A3 (0.63) CNR1EIF4A3MEN1KMT2AIDO1
SCHEMBL29655546 0.77 EIF4A3 (0.63) CNR1EIF4A3MEN1KMT2AIDO1
SCHEMBL29897794 0.77 ULK1 (0.49) CNR1EIF4A3MEN1KMT2AIDO1
SCHEMBL4276853 0.77 ULK1 (0.49) CNR1EIF4A3MEN1KMT2AIDO1
SCHEMBL30536697 0.77 IDO1 (0.38) EIF4A3IDO1TDO2ALOX15
SCHEMBL30147453 0.76 NPC1 (0.48) CNR1EIF4A3MEN1KMT2AKDM4E
SCHEMBL24448445 0.74 EIF4A3 (0.47) CNR1EIF4A3GHSRIDO1TDO2
SCHEMBL30147573 0.74 EIF4A3 (0.47) CNR1EIF4A3GHSRIDO1TDO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12540141-B2 Spiropyrrolidine derived antiviral agents ENANTA PHARMACEUTICALS, INC. (US) 2026-02-03 US disclosed
CN-116621917-A Difluoro indole-spiro compound and preparation method and application thereof 深圳信立泰药业股份有限公司 2023-08-22 CN disclosed
US-20230103494-A1 NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS ENANTA PHARMACEUTICALS, INC. 2023-04-06 US disclosed
CN-114524821-A Novel spiropyrrolidine derived antiviral drugs 英安塔制药有限公司 2022-05-24 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230103494-A1 NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS ACE, ACE2, REN CNR1 1707/4885EIF4A3 179/4885MEN1 4168/4885
US-12540141-B2 Spiropyrrolidine derived antiviral agents ACE2, NR3C2, ACE CNR1 248/4885EIF4A3 352/4885MEN1 3954/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.